UCART22

UCART22 is an allogeneic CAR T-cell therapy developed by Cellectis S.A.. Its target is CD22. The sponsor states: Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells. ClinicalTrials.gov describes the intervention as: Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT04150497, plans to enrol 52 participants with primary completion expected 2026-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.